US Cancer Moonshot Blue Ribbon Panel Unveils Its 10 Recommendations

On September 7, 2016, a Blue Ribbon Panel an offshoot of Vice President Joe Bidens Cancer Moonshot initiative held a conference and announced its 10 Recommendations. These recommendations focus on seven main areas: clinical trials, better and greater data-sharing, cancer immunology, pediatric cancer, precision prevention and early detection, tumor evolution and progression, and the science of implementations. Notably, these recommendations encourage patients to submit their comprehensive tumor profiles with the hope of expanding knowledge about which therapies work, in what populations, and with which types of cancer. They also promote the mining of patient data to predict patient outcomes. Generating a lot of excitement, the recommendations also call for a network devoted exclusively to discovering and evaluating immunotherapy clinical trials.

The Cancer Moonshot Makes Its Way to Europe

The Cancer Moonshot is not limited to the confines of the US. Recently, its task force announced a partnership between US and UK scientists to focus on better cancer detection technology. Furthermore, global discussions have focused on themes of collaboration and transparency. The National Cancer Institute has put these themes into action with the creation of its Genomic Data Commons (GDC). Launched in early June, the GDC has shared more than five petabytes of raw unprocessed genomic data from large research projects on nearly thirty tumor types from more than 14,000 patients, along with associated clinical data (e.g. clinical diagnosis, treatment history, survival data), creating a foundational system for broad sharing and analysis of cancer genomic data, which is critical for advancing the field of precision medicine and improving the care of cancer patients. As a result, this repository of data is now available free of charge to researchers throughout the world. GMAN will continue to monitor developments of the Cancer Moonshot program and how they continue to affect our colleagues worldwide. To learn more, click HERE.

Europe Medicine Agency’s Committee for Medicinal Products for Human Use Adopts a Positive Opinion for the Conditional Approval of Ninlaro (ixazomib) for Use in Patients with Multiple Myeloma

European Medicines Agencys (EMA) Committee for Medicinal Products for Human Use (CHMP) now recommends the conditional approval of Takeda Pharmaceuticals Ninlaro (ixazomib) capsules in combination with lenalidomide and dexamethasone for patients with multiple myeloma who have had at least one prior therapy. If the European Commission ratifies CHMPs positive recommendation, Ninlaro will be authorized as the first and only oral proteasome inhibitor for use throughout the European Economic Area, which includes the European Unions 28 member states as well as Norway, Lichtenstein, and Iceland. To learn more, click HERE.


Patient & Family Seminar in the Czech Republic Is a Success!

In early September, the 2016 Czech Republic Patient & Family Seminar took place in the city of Lazne Belhorad with 130 patients participating in educational sessions with Drs. Roman Hajek, Vladimir Maisnar, Ludek Pour, Jakub Radocha, Jan Straub, and Petr Hylena. Popular presentations included discussions of patient suitability for transplant, management of neuropathy, side effects, and new drugs for myeloma. The leadership and membership of both the Czech Myeloma Group and the Slovak Myeloma Society patient groups were well-represented, and the meetings success was due in part to the long-standing collaboration between these two organizations.

Madrid Hosts Its First Patient & Family Seminar

On September 15, 2016 the Comunidad Espaola Pacientes Con Mieloma Multiple (CEMPP) hosted its first Patient & Family Seminar in collaboration with the International Myeloma Foundation in Madrid. Speakers included Drs. Jesus San Miguel, Maria V. Mateos, Bruno Paiva, and more. Teresa Regueiro Lopez, the Founder and President of CEMPP and a myeloma patient, has been working tirelessly to reach patients throughout Spain, where 2000 new myeloma cases are diagnosed each year. The Madrid Patient & Family Seminar was a great success, with more than 100 participants. For more information about CEMPP, click HERE.


Replay of Living Well with Myeloma Teleconference

IMF Medical Liaison Dr. Rafat Abonour (Indiana University Simon Cancer Center) and Dr. Edward Stadtmauer (University of Pennsylvania) will present on CAR T-Cell Therapy: What Myeloma Patients & Caregivers Need to Know. CAR T-cells, or chimeric antigen receptor T-cells, are part of a class of cancer therapies known as immunotherapies. With CAR T-cell therapy, a patients T-cells are harvested and genetically reengineered to become better able to recognize and attack myeloma. The altered T-cells are then reinfused into the body with the hope of fighting the disease. Replay for this teleconference for free HERE.


We Would Like to Thank Our Sponsors: Takeda Oncology, Celgene, Amgen, and Bristol-Myers Squibb